Nathan Cherny

1 month ago | oncologynewscentral.com | Marcia Frellick |Nathan Cherny |Amber Dance

About 1.48 million bottles of the generic attention-deficit/hyperactivity disorder (ADHD) drug atomoxetine were recalled from the US market by manufacturer Glenmark Pharmaceuticals after tests found potentially harmful impurities above limits imposed by the US Food and Drug Administration (FDA), according to the FDA. Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.

2 months ago | oncologynewscentral.com | Nathan Cherny |Robert A. Figlin

When it comes to end-of-life care for patients with cancer, “I think that there is a real deficit in our training,” says Nathan I. Cherny, MD, director of the Cancer Pain and Palliative Medicine Unit at Shaare Zedek Medical Center in Jerusalem, Israel. Dr. Cherney and colleagues recently examined factors contributing to oncologists overtreating patients at the end of life. He discusses key findings and ways to address this continued problem with Robert A.

Nov 26, 2024 | oncologynewscentral.com | Nathan Cherny

In the evolution of oncologic treatments, new agents are initially introduced as later-line therapies. After their efficacy is established, subsequent studies investigate their use as stand-alone or add-on therapies in earlier lines for metastatic disease before exploring their use as adjuvant therapies for nonmetastatic cancer. This process is referred to as “upstreaming” studies. The aim is to find the optimal place for the treatment over the course of the long-term treatment paradigm.